FDA designations boost AI-Driven cell therapy approach for Duchenne muscular dystrophy

[cafead]

via The FDA has granted Orphan Drug and Rare Pediatric Disease Designations to Somite's cell replacement therapy for the treatment of Duchenne muscular dystrophy.

article source